A GPC2 antibody-drug conjugate is efficacious against neuroblastoma and small-cell lung cancer via binding a conformational epitope

Glypican 2 (GPC2) is a MYCN-regulated, differentially expressed cell-surface oncoprotein and target for immune-based therapies in neuroblastoma. Here, we build on GPC2’s immunotherapeutic attributes by finding that it is also a highly expressed, MYCN-driven oncoprotein on small-cell lung cancers (SC...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cell Rep Med
Hlavní autoři: Raman, Swetha, Buongervino, Samantha N., Lane, Maria V., Zhelev, Doncho V., Zhu, Zhongyu, Cui, Hong, Martinez, Benjamin, Martinez, Daniel, Wang, Yanping, Upton, Kristen, Patel, Khushbu, Rathi, Komal S., Navia, Carmen T., Harmon, Daniel B., Li, Yimei, Pawel, Bruce, Dimitrov, Dimiter S., Maris, John M., Julien, Jean-Philippe, Bosse, Kristopher R.
Médium: Artigo
Jazyk:Inglês
Vydáno: Elsevier 2021
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8324494/
https://ncbi.nlm.nih.gov/pubmed/34337560
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.xcrm.2021.100344
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky